An Open-label Extension Study to Assess the Long-term Safety and Tolerability of Adjunctive KarXT in Subjects with Inadequately Controlled Symptoms of Schizophrenia
This research is an 'open-label extension study', which means everyone involved knows they are receiving the study medicine, KarXT. It's designed for people with schizophrenia whose symptoms aren't fully controlled by their current treatment. The main goal is to check the long-term safety of KarXT and see how well people tolerate it over time. Researchers will be carefully noting any side effects that happen during the study. This is a Phase III study, which means KarXT has already shown some promise in earlier research and is now being tested on a larger group of people before it can be considered for wider use. It's an important step to understand if this new medication could be a helpful option in the future for managing schizophrenia.
At a glance
What is this study about?
This study is looking at a new medicine called KarXT, which is being investigated as an additional treatment for schizophrenia. Schizophrenia is a condition that affects how a person thinks, feels, and behaves. For some people, current treatments don't fully control their symptoms, and this study aims to see if KarXT could be a helpful option. This particular study is an 'open-label extension,' meaning it's a continuation of earlier studies where people have already taken KarXT, and now they will continue to take it while researchers gather more long-term information.
The main purpose of this study is to understand the long-term safety of KarXT. Researchers want to know if there are any side effects that only appear after someone has been taking the medicine for a longer time, and how well people tolerate the medicine generally. They will be carefully recording any health problems that participants experience during the study. They will also pay attention to how many serious side effects occur, and if any side effects lead people to stop taking the study medicine.
This kind of study is really important because it helps medical experts get a complete picture of a new medicine before it can be made widely available. By studying KarXT in this way, we can learn more about how it works, its potential benefits, and any possible long-term risks, which helps doctors make informed decisions about future treatments for people living with schizophrenia.
Key takeaways
- This study evaluates the long-term safety of KarXT for schizophrenia.
- It's an extension for people already taking KarXT in a previous study.
- Researchers will closely monitor for any side effects over time.
- This helps understand if KarXT is a safe long-term treatment option.
- Participation requires being an adult aged 18 or older.
Who may be eligible?
To join this study, you need to be an adult, aged 18 or older. Both men and women are welcome to take part.
Crucially, you would already be participating in a previous study using KarXT for schizophrenia, and your symptoms would not be fully under control with your current treatment. The researchers will check your full medical history and current health to make sure that taking part in this specific continuation study is safe and appropriate for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Are you currently participating in a KarXT study for schizophrenia?
- Are your schizophrenia symptoms not fully controlled by your current treatment?
- Are you willing to attend regular clinic visits for monitoring?
What does participation involve?
If you join this study, you would continue to take the medicine called KarXT, as this is an extension of a previous study. You would have regular visits to the study clinic where the research team would monitor your health very closely. These visits would involve checking for any side effects and seeing how well you are tolerating the medicine. You might have physical examinations, blood tests, and answer questions about your well-being. The total length of your participation would depend on the study design, but generally, these long-term studies can last for several months or even longer, with regular follow-up appointments.
Potential risks and benefits
Locations (1)
- —UnverifiedBulgaria
Common questions
What is an 'open-label' study?
An 'open-label' study means that both you and your study doctor will know that you are receiving the study medicine, KarXT, rather than a dummy pill (placebo) or another treatment.
What does 'adjunctive' mean?
In this study, 'adjunctive' means that KarXT would be added to your current treatment for schizophrenia, rather than replacing it entirely.
What does 'long-term safety' mean?
It means the study will look at any side effects or health problems that might appear over a longer period of time while taking the medicine, not just in the short-term.
What are 'treatment-emergent adverse events (TEAEs)'?
These are simply any health problems or side effects that happen to you after you start taking the study medicine, even if they might not be directly caused by the medicine.
Will I have to pay to be in the study?
No, you will not have to pay to participate in the study. All study-related medication and assessments will be provided at no cost to you.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.